Skip to main content
K

Kangmei Pharmaceutical Co.,Ltd — Investor Relations & Filings

Ticker · 600518 LEI · 3003006FRNBUUTVKBB50 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,366 across all filing types
Latest filing 2026-04-17 Proxy Solicitation & In…
Country CN China
Listing Shanghai Stock Exchange 600518

About Kangmei Pharmaceutical Co.,Ltd

Kangmei Pharmaceutical Co.,Ltd. focuses on the research, development, production, and distribution of Traditional Chinese Medicine (TCM). The company manages an integrated industry chain that includes herbal cultivation, standardized processing of decoction pieces, and the manufacturing of patent medicines. Its offerings extend to health supplements, medical devices, and functional foods. A key component of its operations is the management of large-scale TCM trading centers and logistics hubs designed to standardize the trade of medicinal materials. Through its "Internet + Healthcare" initiatives, the company provides digital health management and pharmaceutical supply chain services, catering to medical institutions, retail pharmacies, and individual consumers.

Recent filings

Filing Released Lang Actions
康美药业关于召开2025年年度股东会的通知
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of the company’s 2025 Annual General Meeting, outlining meeting date, location, agenda items for shareholder approval, voting procedures, and including a proxy form. It is clearly a solicitation of proxies and information statement sent to shareholders to request votes. Therefore, it falls under Proxy Solicitation & Information Statement.
2026-04-17 Chinese
康美药业关于2025年度拟不进行利润分配的公告
Notice of Dividend Amount Classification · 1% confidence The document is a formal announcement by the board regarding the company’s profit distribution plan for 2025, explicitly stating no dividend or capital reserve transfer will be made and providing details of the decision process. It falls squarely under announcements about dividend distributions (even though it is a ‘no distribution’ notice), matching the “Notice of Dividend Amount” category (DIV).
2026-04-17 Chinese
康美药业关于董事、高级管理人员2026年度薪酬方案的公告
Remuneration Information Classification · 1% confidence The document is an announcement entitled “关于董事、高级管理人员2026年度薪酬方案的公告,” outlining the detailed compensation scheme for company directors and senior management for fiscal year 2026. It is not reporting a change in personnel, nor announcing an upcoming report, but rather specifying remuneration policy. This matches the definition of Remuneration Information (Code: DEF 14A).
2026-04-17 Chinese
康美药业2025年年度报告摘要
Annual Report Classification · 1% confidence The document is titled '康美药业股份有限公司2025年年度报告摘要' (Kangmei Pharmaceutical Co., Ltd. 2025 Annual Report Summary). It contains key financial data, business descriptions, and shareholder information for the fiscal year 2025. While it is a summary, it serves as the official disclosure of the annual financial performance and is distinct from a mere announcement of a report's availability. In the context of Chinese A-share filings, the 'Annual Report Summary' (年度报告摘要) is a standard component of the full Annual Report (10-K equivalent) and contains substantive financial data, thus it is classified as an Annual Report. FY 2025
2026-04-17 Chinese
康美药业关于公司2025年度日常关联交易执行情况及2026年度日常关联交易预计的公告
Regulatory Filings Classification · 1% confidence The document is an official corporate announcement by Kangmei Pharmaceutical Company regarding its 2025 actual and 2026 projected related‐party (关联交易) transactions. It is not a full financial report (e.g., Annual Report 10-K or Interim Report IR), nor an AGM presentation, earnings release, management change, share issuance, or any other narrowly defined category. Instead, it is a routine regulatory disclosure required by the exchange/listing rules about related‐party dealings. Since it does not fit any of the specific categories, it defaults to the general Regulatory Filings category (RNS).
2026-04-17 Chinese
康美药业2025年度独立董事述职报告（赖小平）
Governance Information Classification · 1% confidence The document is the full text of an independent director’s annual duties performance report (“独立董事述职报告”), detailing attendance at board and committee meetings, governance activities, internal controls, and committee work. It is not announcing board changes, financial results, dividends, or other transactional updates, nor is it an MD&A of financial performance. Instead, it focuses on governance practices and board oversight, which aligns with the Governance Information category (CGR).
2026-04-17 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.